methylphenidate has been researched along with Tremor in 2 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if repeated dosing with methylphenidate hydrochloride (MPD) (Ritalin; Novartis Pharmaceuticals, East Hanover, NJ), an inhibitor of the dopamine transporter, would augment the effects of oral levodopa in patients with Parkinson disease." | 5.12 | Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. ( Carlson, NE; Carter, JH; Nutt, JG, 2007) |
| " Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer." | 1.36 | Methylphenidate side effects in advanced cancer: a retrospective analysis. ( Davis, MP; Khoshknabi, DS; Lasheen, W; Mahmoud, F; Rivera, N; Walsh, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lasheen, W | 1 |
| Walsh, D | 1 |
| Mahmoud, F | 1 |
| Davis, MP | 1 |
| Rivera, N | 1 |
| Khoshknabi, DS | 1 |
| Nutt, JG | 1 |
| Carter, JH | 1 |
| Carlson, NE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Subacute Trial of Methylphenidate in Parkinson's Disease[NCT00359723] | Phase 2 | 13 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for methylphenidate and Tremor
| Article | Year |
|---|---|
Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Dopamine Uptake Inhibitors; Do | 2007 |
1 other study available for methylphenidate and Tremor
| Article | Year |
|---|---|
Methylphenidate side effects in advanced cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anorexia; Central Nervous System Stimulants | 2010 |